Sex differences in pharmacokinetics and toxicity of antiretroviral therapy

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 2, 2006, Pages 273-283

  Umeh, Obiamiwe C ^a   Currier, Judith S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral therapy; Gender; Pharmacokinetics; Toxicity

Indexed keywords

ANTIRETROVIRUS AGENT;

ANAMNESIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; SEX DIFFERENCE; TOXICITY; AREA UNDER THE CURVE; CLINICAL TRIAL; FEMALE; MALE; META ANALYSIS; METABOLISM;

ANTI-RETROVIRAL AGENTS; AREA UNDER CURVE; CLINICAL TRIALS; FEMALE; HIV INFECTIONS; HUMANS; MALE; META-ANALYSIS; SEX FACTORS;

EID: 33847761503     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.2.273     Document Type: Review

References (49)

1. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): Heterosexual Tranmission Of HIV - 29 States, 1999-2002. MMWR Morb. Mortal. Wkly Rep. (2004) 53(06):125-129.
2. GULICK RM, RIBAUDO HJ, SHIKUMA CM et al.: Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. (2004) 350(18):1850-1861.
3. GIFFORD AL, CUNNINGHAM WE, HESLIN KC et al.: Participation in research and access to experimental treatments by HIV-infected patients. N. Engl. J. Med. (2002) 346(18):1373-1382.
4. ANDERSON PL, KAKUDA TN, KAWLE S, FLETCHER CV: Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS (2003) 17(15):2159-2168.
5. ZHOU XJ, SHEINER LB, D'AQUILA RT et al.: Population pharmacokinetics of nevirapine, zidovudine and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob. Agents Chemother. (1999) 43(1):121-128.
6. LA PORTE C, BURGER D, GYSSENS I, SPRENGER H, KOOPMANS P: Gender differences in nevirapine pharmacokinetics, fact or fiction? Proceedings of the 4th International Workshop on Clinical Pharmacology of HIV therapy. Cannes, France (2003):Abstract 3.1.
7. BURGER DM, LA PORTE CJL, VAN DER ENDE ME, MIESEN WMA, KOOPMANS PP: Gender-related differences in efavirenz pharmacokinetics. Proceedings of the 4th International Workshop on Clinical Pharmacology of HIV therapy. Cannes, France (2003):Abstract 3.6.
8. PFISTER M, LABBE L, HAMMER SM et al.: Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob. Agents Chemother. (2003) 47(1):130-137.
9. BERTZ R, LAM W, HSU A, GRANNEMAN GR, SUN E: Effects of gender, race, age and weight on the pharmacokinetics of lopinavir (lopinavir/ritonavir) in healthy adult subjects™ after single-dose kaletra. Proceedings of the 2nd International Workshop on Clinical Pharmacology of HIV therapy. Noordwijk, The Netherlands (2001):Abstract 3.12.
10. POIRIER JM, ZOUAI O, MEYNARD JL et al.: Lack of effect of gender, age, weight and body mass index on trough lopinavir plasma concentrations in HIV-pretreated patients treated with Kaletra. Proceedings of the 4th International Workshop on Clinical Pharmacology of HIV therapy. Cannes, France (2003):Abstract 6.12.
11. BURGER DM, MULLER RJ, VAN DE LEUR MR, LA PORTE CJL: Lopinavir plasma levels are significantly higher in female than in male HIV-1 infected patients. Proceedings of the 3rd International Workshop on Clinical Pharmacology of HIV therapy. Washington DC, USA (2002):Abstract 6.5.
12. GATTI G, DE PASCALIS CR, DE LUCA A et al.: Predictors of amprenavir parameters of drug exposure in heavily pretreated HIV positive patients. Proceedings of the 6th International Congress on Drug therapy in HIV infection. Glasgow, Scotland, UK (2002):Abstract P165.
13. PAI MP, SCHRIEVER CA, DIAZ-LINARES M, NOVAK RM, RODVOLD KA: Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. Pharmacotherapy. (2004) 24(5):592-599.
14. FLETCHER CV, JIANG H, BRUNDAGE RC et al.: Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J. Infect. Dis. (2004) 189(7):1176-1184.
15. DICKINSON L, BACK D, CHANDLER B et al.: The impact of gender on saquinavir hard-gel/ritonavir (1000/100 mg b.i.d.) pharmacokinetics and PBMC transporter expression in HIV-1 infected individuals. Proceedings of the 6th International Workshop on Clinical Pharmacology of HIV therapy. Quebec City, Canada (2005):Abstract 9.
16. ROBERTSON S, FALLOON J, FORMENTINI E, ALFARO R, PENZAK S: Lack of sex-related differences in saquinavir pharmacokinetics in an HIV seronegative cohort. Proceedings of the 6th International Workshop on Clinical Pharmacology of HIV therapy. Quebec city, Canada (2005):Abstract 50.
17. BURGER DM, SIEBERS MC, HUGEN PW, AAMOUTSE RE, HEKSTER YA, KOOPMANS PP: Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? J. Acquir. Immune Defic. Syndr. (2002) 29(1):101-102.
18. BURGER D, BOYD M, DUNCOMBE C et al.: Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J. Antimicrob. Chemother. (2003) 51(5):1231-1238.
19. RIBERA E, LOPEZ RM, DIAZ M et al.: Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus mini-dose ritonavir in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. (2004) 48(11):4256-4262.
20. MOULD DR, ZHANG X, NIEFORTH K, SALGO M, BUSS N, PATEL IH: Population pharmacokinetics and exposure-response relationship of enfurvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clin. Pharmacol. Ther. (2005) 77(6):515-528.
21. OFOTOKUN I, POMEROY C: Sex differences in adverse reactions to antiretroviral drugs. Top. HIV Med. (2003) 11(2):55-59.
22. MOORE RD, FORTGANG I, KERULY J, CHAISSON RE: Adverse events from drug therapy for human immunodeficiency virus disease. Am. J. Med. (1996) 101(1):34-40.
23. + responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J. Acquir. Immune Defic. Syndr. (2000) 24(4):316-324.
24. SQUIRES K, GULICK R, PAVIA A et al.: Sex differences in the selection of thymidine analog regimen therapy trials (START I and START II). Proceeding of the 7th conference on Retroviruses and Opportunistic Infections. San Francisco, US (2000):Abstract 516.
25. KUMAR P, RODRIGUEZ-FRENCH A, THOMPSON M et al.: Prospective study of hyperlipidemia in ART-naïve subjects taking combivir/abacavir (COM/ABC), COM/nelfinavir (NFV), or stavudine (d4T)/lamivudine (3TC)/NFV (ESS40002). Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, US (2002):Abstract 33.
26. BERSOFF-MATCHA SJ, MILLER WC, ABERG JA et al.: Sex differences in nevirapine rash. Clin. Infect. Dis. (2001) 32(1):124-129.
27. MAZHUDE C, JONES S, MURAD S, TAYLOR C, EASTERBROOK P: Female sex, but not ethnicity, is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS (2002) 16(11):1566-1568.
28. SANNE I, MOMMEJA-MARIN H, HINKLE J et al.: Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J. Infect. Dis. (2005) 191(6):825-829.
29. SHEPARD KV: Important new safety information. Re: clarification of risk factors for severe, life-threatening and fatal hepatotoxicity with Viramune (nevirapine). Feb (2004). Dear health care professional letter.
30. LUCAS GM, CHAISSON RE, MOORE RD: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. (1999) 131(2):81-87.
31. CURRIER JS, YETZER E, POTHOFF A et al.: Gender differences in adverse events on ritonavir intolerance. Proceedings of 1997 National Conference on Women and HIV. Pasadena, US (1997):Abstract 304.7.
32. BONFANTI P, GULISANO C, RICCI E et al.: Risk factors for lipodystrophy in the CISAI cohort. Biomed. Pharmacother. (2003) 57(9):422-427.
33. PERNERSTORFER-SCHOEN H, JILMA B, PERSCHLER A: Sex differences in HAART-associated dyslipidemia. AIDS (2001) 15(6):725-734.
34. GANDHI M, AWEEKA F, GREENBLATT RM, BLASCHKE TF: Sex differences in pharmacokinetics and pharmacodynamics. Ann. Rev. Pharmacol. Toxicol. (2004) 44:499-523.
35. KNIGHT LC, PARKMAN HP, BROWN KL et al.: Delayed gastric emptying and decreased antral contractility in normal premenopausal women compared with men. Am. J. Gastroenterol. (1997) 92(6):968-975.
36. PINES A, ECKSTEIN N, DOTAN I et al.: Effect of estradiol on rat ileum. Gen. Pharmacol. (1998) 31(5):735-736.
37. BARAONA E, ABITTAN CS, DOHMEN K et al.: Gender differences in pharmacokinetics of alcohol. Alcohol. Clin. Exp. Res. (2001) 25(4):502-507.
38. PAINE MF, LUDINGTON SS, CHEN ML et al.: Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression. Drug Metab. Dispos. (2005) 33(3):426-433.
39. WILSON K: Sex-related differences in drug disposition in man. Clin. Pharmcokinet. (1984) 9(3):189-202.
40. ANDERSON GD: Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics and pharmacodynamics. J. Womens Health (Larchmt) (2005) 14(1):19-29.
41. ZHU B, LIU ZQ, CHEN GL et al.: The distribution and gender difference of CYP3A activity in Chinese subjects. Br. J. Clin. Pharmacol. (2003) 55(3):264-269.
42. COTREAU MM, VON MOLTKE LL, GREENBLATT DJ: The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin. Pharmacokinet. (2005) 44(1):33-60.
43. ABERNETHY DR, GREENBLATT DJ, SHADER RI: Imipramine disposition in users of oral contraceptive steroids. Clin. Pharmacol. Ther. (1984) 35(6):792-797.
44. MINERS JO, GRGURINOVICH N, WHITEHEAD AG, ROBSON RA, BIRKETT DJ: Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid. Br. J. Clin. Pharmacol. (1986) 22(2):135-142.
45. http://www.unaids.org/bangkok2004/GAR2004_pdf/Chapter2_globaloverview_en. pdf AIDS epidemic update: December (2004). UNAIDS.
46. http://grants.nih.gov/grants/guide/notice-files/not94-100.html NIH guidelines on the inclusion of women and minorities as subjects in clinical research. NIH Guide (1994).
47. http://www.clinicaltrials.gov/ct/show/NCT00102986;jsessionid=CD7053FA063 4549133AA502A45286E61?order=3 Differences in blood levels of lopinavir/ritonavir in HIV-infected men and women. Clinical Trials.Gov Publication (2005).
48. http://www.fda.gov/cder/foi/label/2005/021814lbl.pdf Tipranavir package insert (2005).
49. http://www.fuzeon.com/common/fpi.pdf Fuzeon package insert (2005).